401567-12-2

Basic information

• Product Name: 1H-Benzimidazole,2-chloro-5-fluoro-1-methyl-(9CI)
• Synonyms: 1H-Benzimidazole,2-chloro-5-fluoro-1-methyl-(9CI);2-chloro-5-fluoro-1-Methyl-1H-1,3-benzodiazole
• CAS NO: 401567-12-2
• Molecular Formula: C8H6ClFN2
• Molecular Weight: 184.5980432
• Product Categories: BENZIMIDAZOLE
• Mol File: 401567-12-2.mol

Chemical Properties

• Boiling Point: 307.997 °C at 760 mmHg
• Flash Point: 140.072 °C
• Appearance: /
• Density: 1.408 g/cm³
• CAS DataBase Reference: 1H-Benzimidazole,2-chloro-5-fluoro-1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,2-chloro-5-fluoro-1-methyl-(9CI)(401567-12-2)
• EPA Substance Registry System: 1H-Benzimidazole,2-chloro-5-fluoro-1-methyl-(9CI)(401567-12-2)

Safety Data

• Hazardous Substances Data: 401567-12-2(Hazardous Substances Data)

Usage

Structure

Benzene ring fused to an imidazole ring
Chlorine and fluorine atoms present
Methyl group present
Potential applications in medicinal chemistry
Biological and pharmacological activities
Requires further research and testing for specific uses and benefits

Upstream product

• 401567-11-1 5-fluoro-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-2-one 
• 131780-97-7 (4-Fluoro-2-nitro-phenyl)-methyl-amine 
• 401567-10-0 4-fluoro-N₁-methylbenzene-1,2-diamine 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 704-05-2 (4-fluoro-2-nitrophenyl)-(methyl)amine 
• 1544-75-8 5-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 108662-49-3 2-chloro-5-fluoro-1H-benzo[d]imidazole 
• 74-88-4 methyl iodide 
• 367-31-7 4-fluoro-1,2-phenylenediamine 

Relevant articles and documents

SMALL MOLECULE REGULATORS OF STEROID RECEPTOR COACTIVATORS AND METHODS OF USE THEREOF

Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.